170 related articles for article (PubMed ID: 24191126)
1. Is CA72-4 a useful biomarker in differential diagnosis between ovarian endometrioma and epithelial ovarian cancer?
Anastasi E; Manganaro L; Granato T; Benedetti Panici P; Frati L; Porpora MG
Dis Markers; 2013; 35(5):331-5. PubMed ID: 24191126
[TBL] [Abstract][Full Text] [Related]
2. Role of biomarkers CA-125, CA-15.3 and CA-19.9 in the distinction between endometriomas and ovarian neoplasms.
Magalhães JS; Jammal MP; Crispim PCA; Murta EFC; Nomelini RS
Biomarkers; 2021 May; 26(3):268-274. PubMed ID: 33554683
[TBL] [Abstract][Full Text] [Related]
3. Clinical Usefulness of Cancer Antigen (CA) 125, Human Epididymis 4, and CA72-4 Levels and Risk of Ovarian Malignancy Algorithm Values for Diagnosing Ovarian Tumors in Korean Patients With and Without Endometriosis.
Shin KH; Kim HH; Kwon BS; Suh DS; Joo JK; Kim KH
Ann Lab Med; 2020 Jan; 40(1):40-47. PubMed ID: 31432638
[TBL] [Abstract][Full Text] [Related]
4. The use of HE4, CA125 and CA72-4 biomarkers for differential diagnosis between ovarian endometrioma and epithelial ovarian cancer.
Anastasi E; Granato T; Falzarano R; Storelli P; Ticino A; Frati L; Panici PB; Porpora MG
J Ovarian Res; 2013 Jul; 6(1):44. PubMed ID: 23816286
[TBL] [Abstract][Full Text] [Related]
5. Clinical Value of Serum HE4, CA125, CA72-4, and ROMA Index for Diagnosis of Ovarian Cancer and Prediction of Postoperative Recurrence.
Wang Q; Wu Y; Zhang H; Yang K; Tong Y; Chen L; Zhou Q; Guan S
Clin Lab; 2019 Apr; 65(4):. PubMed ID: 30969083
[TBL] [Abstract][Full Text] [Related]
6. Role of HE4, CA72.4, and CA125 in monitoring ovarian cancer.
Granato T; Midulla C; Longo F; Colaprisca B; Frati L; Anastasi E
Tumour Biol; 2012 Oct; 33(5):1335-9. PubMed ID: 22528938
[TBL] [Abstract][Full Text] [Related]
7. Increased cathepsin L levels in serum in some patients with ovarian cancer: comparison with CA125 and CA72-4.
Nishida Y; Kohno K; Kawamata T; Morimitsu K; Kuwano M; Miyakawa I
Gynecol Oncol; 1995 Mar; 56(3):357-61. PubMed ID: 7705668
[TBL] [Abstract][Full Text] [Related]
8. [Usefulness of determining tumor markers CEA, CA125 and CA72-4 in blood serum of patients with ovarian carcinoma].
Kokocińska D; Worwag J; Tomala J; Dzieciuchowicz L; Nowak S; Kuśmierski S
Ginekol Pol; 1994 Sep; 65(9):495-501. PubMed ID: 7721162
[TBL] [Abstract][Full Text] [Related]
9. The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis.
Kadija S; Stefanovic A; Jeremic K; Radojevic MM; Nikolic L; Markovic I; Atanackovic J
Int J Gynecol Cancer; 2012 Feb; 22(2):238-44. PubMed ID: 22214964
[TBL] [Abstract][Full Text] [Related]
10. Assessment of protein biomarkers for preoperative differential diagnosis between benign and malignant ovarian tumors.
Landolfo C; Achten ETL; Ceusters J; Baert T; Froyman W; Heremans R; Vanderstichele A; Thirion G; Van Hoylandt A; Claes S; Oosterlynck J; Van Rompuy AS; Schols D; Billen J; Van Calster B; Bourne T; Van Gorp T; Vergote I; Timmerman D; Coosemans A
Gynecol Oncol; 2020 Dec; 159(3):811-819. PubMed ID: 32994054
[TBL] [Abstract][Full Text] [Related]
11. Serum HE4 as a useful biomarker in discriminating ovarian cancer from benign pelvic disease.
Zheng H; Gao Y
Int J Gynecol Cancer; 2012 Jul; 22(6):1000-5. PubMed ID: 22426406
[TBL] [Abstract][Full Text] [Related]
12. The value of CA 125 and CA72-4 in management of patients with epithelial ovarian cancer.
Fayed ST; Ahmad SM; Kassim SK; Khalifa A
Dis Markers; 1998 Nov; 14(3):155-60. PubMed ID: 10427474
[TBL] [Abstract][Full Text] [Related]
13. Rupture of an endometrioma with extremely high serum CA-125 level (> 10,000 IU/ml) and ascites resembling ovarian cancer.
Park CM; Kim SY
Eur J Gynaecol Oncol; 2014; 35(4):469-72. PubMed ID: 25118496
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of combined detection of serum tumor markers in diagnosis of patients with ovarian cancer.
Bian J; Li B; Kou XJ; Liu TZ; Ming L
Asian Pac J Cancer Prev; 2013; 14(11):6241-3. PubMed ID: 24377511
[TBL] [Abstract][Full Text] [Related]
15. Comparison between Serum HE4 and CA125 as Tumor Markers in Premenopausal Women with Benign Pelvic Mass.
Huang X; Wang Y; He X; Kang F; Luo L; Su Z; Ye H
Clin Lab; 2019 May; 65(5):. PubMed ID: 31115211
[TBL] [Abstract][Full Text] [Related]
16. The concomitant determination of different tumor markers in patients with epithelial ovarian cancer and benign ovarian masses: relevance for differential diagnosis.
Gadducci A; Ferdeghini M; Prontera C; Moretti L; Mariani G; Bianchi R; Fioretti P
Gynecol Oncol; 1992 Feb; 44(2):147-54. PubMed ID: 1312052
[TBL] [Abstract][Full Text] [Related]
17. Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response.
Hamed EO; Ahmed H; Sedeek OB; Mohammed AM; Abd-Alla AA; Abdel Ghaffar HM
Diagn Pathol; 2013 Jan; 8():11. PubMed ID: 23343214
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of CA125 and CA72-4 in gastric cancer with peritoneal dissemination.
Emoto S; Ishigami H; Yamashita H; Yamaguchi H; Kaisaki S; Kitayama J
Gastric Cancer; 2012 Apr; 15(2):154-61. PubMed ID: 21892754
[TBL] [Abstract][Full Text] [Related]
19. [The clinical usefulness of serum CA72-4 analysis in patients with ovarian cancer].
Kobayashi H
Nihon Sanka Fujinka Gakkai Zasshi; 1989 May; 41(5):585-9. PubMed ID: 2754289
[TBL] [Abstract][Full Text] [Related]
20. Differential diagnosis of ovarian cancer, benign ovarian tumor and endometriosis by a combination assay of serum sialyl SSEA-1 antigen and CA125 levels.
Iwanari O; Miyako J; Date Y; Nakayama S; Kijima S; Moriyama M; Takahashi K; Yoshino N; Karino K; Endoh J
Gynecol Obstet Invest; 1990; 29(1):71-4. PubMed ID: 1972127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
